Recent developments highlight Biofrontera's Q2 2026 financial results, including strong revenue growth and a net loss, alongside earnings transcripts and prior quarterly reports.

• Biofrontera posted strong Q2 2026 results with 33% revenue growth [N1].
• The company reported a Q2 2026 net loss but revenue exceeded expectations [N2].
• Biofrontera released its Q1 2026 earnings transcript and reported a Q1 loss with revenue above estimates [N7,N8].
• The company filed a 10-K/A for fiscal year 2025 and a 10-Q for Q2 2026 providing detailed financial disclosures [S1,S2].

The company has demonstrated revenue growth of 33% in Q2 2026, indicating positive market acceptance and sales momentum [N1]. Biofrontera's ability to exceed revenue expectations despite reporting a net loss suggests operational progress and potential for improved financial performance [N2]. The company maintains liquidity with a current ratio of 1.18, supporting ongoing operations [S2].

Biofrontera reported a net loss of $604,000 in Q2 2026 with negative earnings per share, indicating ongoing profitability challenges [S2]. The cash ratio of 0.44 suggests limited cash coverage relative to current liabilities, which may constrain financial flexibility [S2]. The company operates as a smaller reporting company and emerging growth company, which may imply limited scale and higher risk exposure [S1].

Biofrontera's moat is not explicitly detailed in the available disclosures. However, the company appears to operate in a specialized niche within dermatology, supported by regulatory approvals and product development milestones referenced in news coverage. The company's ability to grow revenue while managing losses suggests some competitive positioning, but detailed competitive advantages or barriers to entry are not explicitly disclosed in the provided data.

• Profitability Risk: The company reported net losses and negative earnings per share in recent quarters, indicating challenges in achieving profitability.
• Liquidity Risk: With a cash ratio below 0.5, Biofrontera's cash reserves may be insufficient to cover short-term liabilities without additional financing.
• Market and Competitive Risk: Operating in a specialized dermatology niche, the company faces competition and regulatory risks that could impact product acceptance and revenue growth.

• Biofrontera Inc. is a publicly traded company on Nasdaq under ticker BFRI [S1].
• The company is incorporated in Delaware and headquartered in Woburn, Massachusetts, USA [S1].
• Biofrontera's common stock has a par value of $0.001 per share and is listed on Nasdaq [S1].
• As of March 16, 2026, Biofrontera had 11,648,323 shares outstanding [S1].
• Biofrontera is classified as a smaller reporting company and an emerging growth company [S1].
• The company filed a 10-K/A for fiscal year ended December 31, 2025, and a 10-Q for the quarter ended June 30, 2026 [S1,S2].
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only [S2].
• As of June 30, 2026, Biofrontera had cash and cash equivalents of $4.659 million and current assets of $12.435 million [S2].
• Current liabilities as of June 30, 2026 were $10.541 million, resulting in a current ratio of 1.18 and a cash ratio of 0.44 [S2].
• The company reported a net loss of $604,000 for the quarter ended June 30, 2026 [S2].
• Basic and diluted earnings per share for Q2 2026 were both -$0.05 [S2].
• Biofrontera reported annual revenue of $28.674 million for the fiscal year ended December 31, 2022 [S2].
• Recent news reports indicate Biofrontera posted strong Q2 2026 results with 33% revenue growth [N1].
• Biofrontera reported a Q2 2026 loss but revenue exceeded expectations according to recent news [N2].
• The company has publicly disclosed earnings transcripts for Q1 2026 and Q4 2025 [N7,N15].